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Abstract
The study examined the effects of a norepinephrine transporter (NET) inhibitor reboxetine (RBX)
on an attentional performance test. Adult SD rats trained with five-choice serial reaction time task
(5-CSRTT) were administered with RBX (0, 3.0 and 10 mg/kg) in the testing day. Alpha-1
adrenergic receptor antagonist PRA and alpha-2 adrenergic receptor antagonist RX821002 were
used to clarify the RBX effect. Results revealed that rat received RBX at 10 mg/kg had an increase
in the percentage of the correct response and decreases in the numbers of premature response.
Alpha-1 adrenergic receptor antagonist Prazosin (PRA) at 0.1 mg/kg reversed the RBX augmented
correct responding rate. However, alpha-2 adrenergic receptor antagonist RX821002 at 0.05 and
0.1 mg/kg dose dependently reversed the RBX reduced impulsive responding. Our results
suggested that RBX as a norepinephrine transporter inhibitor can be beneficial in both attentional
accuracy and response control and alpha-1 and alpha-2 adrenergic receptors might be involved
differently.
Background
The action of norepinephrine (NE) can be terminated not
only by enzymes that destroy NE but also by a transport
pump for NE, i.e., removing it from the synapse without
destroying it. The transport pump that terminates the syn-
aptic action of NE is called NE "transporter" or abbrevi-
ated as NET. NET locates in the pre-synaptic terminal and
acts to remove NE out of the synaptic cleft thus stops its
action [1]. In terms many issues of the selectivity and
mechanisms of action remained unresolved, selective NET
inhibitor has now been developed to treat a variety of
brain-related disorders, including depression, attention
deficit hyperactivity disorder (ADHD), post-traumatic
stress disorder (PTSD) and cocaine dependence [1-4].
Reboxetine (RBX) is the first potent, selective and specific
NE transporter inhibitor that has been marketed as an
antidepressant [5]. Most of the previous studies focused
on the antidepressant activity of RBX in rodents [6] in
which RBX exhibited an exceptional antidepressant effect
[7]. Nevertheless there is relatively lack of study examin-
ing the effect of RBX on the aspect of response control and
attentional function. The latter is worth to address given
Published: 14 August 2009
Journal of Biomedical Science 2009, 16:72 doi:10.1186/1423-0127-16-72
Received: 6 March 2009
Accepted: 14 August 2009
This article is available from: http://www.jbiomedsci.com/content/16/1/72
© 2009 Liu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The cost of publication in Journal of Biomedical Science
is bourne by the National Science Council, Taiwan.Journal of Biomedical Science 2009, 16:72 http://www.jbiomedsci.com/content/16/1/72
Page 2 of 12
(page number not for citation purposes)
the fact the disturbed amount of synaptic NE generally
associated with the symptoms such as impaired attention,
problems concentrating, slowness of information process-
ing and poor response control [8,9]. The present experi-
ment therefore aimed to examine the RBX-induced
attentional changes by employing a recognized behavio-
ral test, named five-choice serial reaction time task (5-
CSRTT).
The 5-CSRTT was modeled after Leonard's five-choice
serial task [10], which was commonly used to assess the
behavioral effects of different forms of arousal in humans
[11]. In the 5-CSRTT, animals are required to discrimi-
nate, spatially, a short visual stimulus occurring randomly
in one of five locations after a scheduled waiting period.
The test requires that the rat must be able to attend to the
array of openings in a specially designed apparatus in
order to detect the discriminative stimulus and respond
correctly to it. Accurate responding requires attention
both in the temporal and spatial domains, thus, providing
a high degree of parametric flexibility and the potential
for independent assessments of the spatial and temporal
components of attention [12]. Furthermore, the 5-CSRTT
provides measures of 'premature' responding, as the ani-
mals need to wait for the imperative visual stimulus prior
to making a discriminative response [13]. The 5-CSRTT
could be widely used to separate animals with deficits in
their attentional processes from other behavioral or cog-
nitive features, for example, locomotor activity when add-
ing with a pair of infra-red beams in the testing box, food-
related motivation in terms of the speed in collecting
earned food pellets [14] and motoric impulsivity as
recording the numbers of premature response prior to the
occurrence of visual signal [15,16].
In the present study, the 5-CSRTT was aimed to manifest
drug-induced attention/impulsivity modifications by clar-
ifying whether RBX treated rats could exhibit less prema-
ture responding or better accuracy of detecting visual
target stimuli as they did when applied to humans in the
recovery from depressive state. The authors designed a
series of experiments to investigate the effects of RBX on
the performance of the 5-CSRTT in rats in order to assess
the benefits of RBX concerning the function of visual
attention and the capacity of response control. The per-
formance of 5-CSRTT was examined in rats following the
administration of RBX, PRA and RX821002. The latter two
were selective agents to antagonize alpha-1 and alpha-2
adrenergic receptors, respectively, and thus were used to
test the possibility of reversing the RBX effects on the per-
formance of the 5-CSRTT. The results obtained from this
study may contribute to the understanding of the func-
tional role of NET inhibitor and be helpful for further
clinical implementations.
Materials and methods
Subjects
A total of 57 male Sprague-Dawley rats (National Labora-
tory Animal Center, Taiwan R.O.C.) aged approximately 4
months and weighted 300350 gm at the start of the exper-
iment were selected. All rats were housed in a tempera-
ture-humidity-controlled holding facility with 12-hour
light/dark cycles (light on from 07:00 to 19:00). All rates
received ad libitum water. However, food was restricted to
that earned during the test sessions [maximum of 100 ×
45 mg purified rodent pellets (Labdiet, USA) and 20 gm/
rat standard rodent chow (TSE, Taiwan) at the end of the
test. The test took place between 08:00 and 18:00 with all
rats being tested at the same time every day where possi-
ble. All experiment procedures were evaluated and per-
mitted to perform by the animal care committee of
National Defense Medical Center with the permission
code number IACUC-04-156. All efforts were made to
reduce the numbers of animals used and to minimize ani-
mal suffering during the experiment.
Apparatus
The apparatus (TSE, Germany) used in this study was very
similar to those described in other studies [17,18]. It con-
sisted of four 25 × 25 cm aluminium operant chambers
without levers and each of them accompanied with a
curved rear wall. Set into the curved wall were five, 2.5 cm
square holes, 4 cm deep and 2.5 cm above a wire mesh
floor. Each hole had an infrared photocell beam to mon-
itor its entrance. Illumination of each hole was provided
by a 3W bulb located at the rear of the hole. Reinforce-
ment was provided by a food-pellet dispenser to deliver
pellets into a magazine at the front of the chamber. The
chamber was illuminated by a 3W house-light mounted
in the centre of the ceiling. The rats were introduced to the
chamber through a hinged Perspex flap in the top half of
the front wall. The chamber was contained within a
sound-attenuating wooden box. Ventilation was supplied
by means of a fan, providing a low level of background
noise that masked extraneous sound. On-line control of
the apparatus and data collection were performed by
using a microcomputer.
Training procedure
Food deprivation
Rats were instructed to the restricted feeding regimen one
week prior to training programs with standard rodent
chow, and gradually reached 90% of their free feeding
weight.
Magazine training
Initial shaping consisted of a magazine training, whereby
the rats learned that food was available in the magazine in
which the hinged metal panel was wedged open with sur-
plus pellets. At this stage, rats were exposed to the boxesJournal of Biomedical Science 2009, 16:72 http://www.jbiomedsci.com/content/16/1/72
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for 15 minutes per session. Once all rats reliably ate all
food pellets within a session, the rats were moved onto a
fixed interval schedule.
Fixed interval schedule
From the following 3 days, rats were placed in the dark
chamber 20 minutes per day with a fixed time schedule,
in which a food pellet was delivered every 20 seconds into
the magazine.
Five-choice serial reaction time task (5-CSRTT)
Every rat was consistently placed in the same chamber and
well-trained in the 5-CSRTT. A session terminated after a
maximum of 100 completed trials or after 30 minutes. A
trial started with the illumination of magazine until rats to
response with a nose-poke response. After a delay (the
intertrial interval, ITI), the stimulus light was presented
over the hole in pseudorandom order. If the rat then
broke a photo-beam crossing by nose-poke within a lim-
ited hold of 5 s, a food pellet was delivered into the mag-
azine. An ITI began if the food pellet was retrieved and the
next stimulus light presented after the ITI. A period of
time-out (i.e., a period of darkness for 5 seconds) would
be followed by an incorrect response or an error of omis-
sion with the house-light extinguished, and during which
no stimuli were presented. After a time-out, the rats
started a new ITI by nose poking to magazine. Figure 1
provided a schematic illustration of 5-CSRTT used in the
present study.
The acquisition of the 5-CSRTT was divided into several
sub-stages based on a scheduled stepped descending
sequence of stimulus duration at 60, 32, 16, 8, 4, 2, 1.5
and finally 1.0 seconds. For these sub-stages, rats were
required to meet all of the following criteria in continuous
3 sessions before passing on to the next training stage: (1)
More than 80 trials were carried out within a period of 30
minutes; (2) Omission rate was less than 20%; (3) An
accuracy rate of 80% or more was achieved; and (4) The
numbers of premature response were less than 30.
Measures and analysis
Accuracy of performance was measured by the calculation
of the percentage of correct response [correct responses/
(correct responses + incorrect responses)]. An error of
omission was scored if the rat failed to respond suffi-
ciently soon after the stimulus onset. A premature
response was scored if the rat responded in any hole dur-
ing the ITI. To assess speed of responding, correct latency
was measured as time elapsing between the occurrence of
visual stimulus and a nose poke in the correct hole. Mag-
azine latency was measured as time elapsing between a
nose poke in the correct hole and retrieving reward in the
magazine.
Obtained data was analyzed using SPSS (version 12.0) for
variables of interest. In experiment 1, one-way ANOVA
was conducted with dose as a non-repeated factor. In
experiment 2, one-way ANOVA was conducted with dose
as a repeated factor. In experiment 3, two-way ANOVA
was conducted with both treatment and dose as repeated
factors. Further analyses and post-hoc comparisons were
performed if necessary. A p value < 0.05 was considered
statistically significant.
Drugs and experimental design
Drugs
The performance of 5-CSRTT was examined after the
administration of vehicle (0.9% saline solution) or the
following drugs: RBX (sponsored by Pfizer Pharmaceutics,
USA), PRA (Sigma, USA) and RX821002 (Sigma, USA).
All drugs were administered in a volume of 2 ml/kg and
were diluted in isotonic saline. RBX was administered
intraperitoneally 60 minutes prior to the test whereas for
PRA or RX8212002, 10 minutes before the test. The doses
used were 10 mg/kg for RBX, 0.1 and 0.3 mg/kg for PRA,
and 0.05 and 0.1 mg/kg for RX821002.
Experiment 1: dose-response study of RBX in the 5-CSRTT
Twenty-four rats reached the acquisition criteria level of 5-
CSRTT (i.e., 1.0 sec of stimulus duration) were used. Rats
were tested their 5-CSRTT performance after the adminis-
tration of RBX (0, 3 and 10 mg/kg). The number of animal
was 8 for each dose. RBX was injected intraperitoneally 60
minutes prior to the test.
Experiment 2: dose-response study of PRA and RX821002 in the 
5CSRTT
Twenty-three rats were examined their 5-CSRTT perform-
ance 10 min later following PRA (N = 11) or RX821002
(N = 12) administration. Each rat received three dose con-
ditions (for PRA, 0, 0.1 and 0.3 mg/kg; for RX821002, 0,
0.05 and 0.1 mg/kg). The order of injection condition was
based on a Latin Square design. Each test session was pre-
ceded by two control sessions in which saline vehicle was
administered.
Experiment 3: The interaction of RBX with PRA or RX in the 5-
CSRTT
Ten rats were examined their 5-CSRTT performance under
the following 4 conditions (vehicle + vehicle, RBX + vehi-
cle, vehicle + PRA, RBX + PRA). The dose for RBX was 10
mg/kg and for PRA, 0.3 mg/kg. Another 10 rats were
examined their 5-CSRTT performance under the following
4 conditions (vehicle + vehicle, RBX + vehicle, vehicle +
RX821002, RBX + RX821002). The dose for RBX was 10
mg/kg and for RX821002, 0.1 mg/kg. The order of injec-
tion condition was based on a Latin Square design. Each
test session was preceded by two control sessions in which
saline vehicle was administered.Journal of Biomedical Science 2009, 16:72 http://www.jbiomedsci.com/content/16/1/72
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Results
Effect of RBX on 5-CSRTT
Effects of RBX on performance of the 5-CSRTT were
shown in Figure 2. RBX was found to altered rats' 5-CSRTT
performance in all aspects. (correct response, F(2,21) =
3.89, p < 0.05; premature response, F(2,21) = 6.33, p <
0.01; omission rate, F(2,21) = 4.24, p < 0.05; correct
latency, F(2,21) = 6.86, p < 0.01 and magazine latency,
F(2,21)= 7.01, p < 0.01). Further analyses by Dunnett's
test revealed that the difference was mainly contributed
from the condition between vehicle and 10 mg/kg RBX.
Effects of PRA or RX821002 on 5-CSRTT
Effects of alpha-1 adrenergic receptor antagonist PRA were
shown in Figure 3. PRA appeared to have no effect on any
of the measures [F(2,20) = 0.18 for correct response;
F(2,20) = 0.72 for premature response; F(2,20) = 0.78 for
omission rate; F(2,20) = 0.31 for correct latency and
F(2,20) = 0.48 for magazine latency]. Effects of alpha-2
adrenergic receptor antagonist RX821002 were shown in
Figure 4. RX821002 had minor effects on accurate
responding and latency to respond or collect food
[F(2,22) = 0.02 for correct response; F(2,22) = 0.66 for
Schematic illustration of the 5-CSRTT used in the present experiment Figure 1
Schematic illustration of the 5-CSRTT used in the present experiment. Rat was placed in the center of the chamber. 
A trial started with the illumination of magazine until rat made a nose-poke response. After a delay (the intertrial interval, ITI), 
the stimulus light was presented over the hole in pseudorandom order. If an animal respond with a nose-poke into the illumi-
nated hole within a limited hold of 5 s, a pellet was delivered into the magazine. An ITI began when the food pellet was 
retrieved, with the next stimulus light presented after the ITI. A period of time-out would be followed by an incorrect 
response with the house-light on for 5 seconds, during which no stimuli were presented. After a timeout, the rat could start a 
new ITI by nose-poking to magazine. Analyses of measures were based on the formulations as indexed.
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Effects of RBX on the performance of 5-CSRTT Figure 2
Effects of RBX on the performance of 5-CSRTT. The graphs showed the effects of RBX (0, 3.0 and 10 mg/kg, N = 8 for 
each dose) on the performance of 5-CSRTT in the aspects of correct response rate (A), premature response (B), omission 
rate (C), correct latency (D) and magazine latency (E). Open bars depicted baseline vehicle controls, oblique lattice bars 
depicted RBX at 3 mg/kg, and black bars depicted RBX at 10 mg/kg. Values are presented as mean+SEM. Student-t test were 
used for each RBX treatment as compared with vehicle condition, * P < 0.05, ** P < 0.01.
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Effects of PRA on the performance of 5-CSRTT Figure 3
Effects of PRA on the performance of 5-CSRTT. The graphs showed the effects of different dosage of PRA (0, 0.1 and 
0.3 mg/kg) on the performance of 5-CSRTT (N = 11) in the aspects of correct response rate (A), premature response (B), 
omission rate (C), correct latency (D) and magazine latency (E). Open bars depicted saline vehicle controls, oblique lattice bars 
depicted PRA at 0.1 mg/kg, and black bars depicted PRA at 0.3 mg/kg. Values are presented as mean+SEM. * P < 0.05.
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Effects of RX821002 on the performance of 5-CSRTT Figure 4
Effects of RX821002 on the performance of 5-CSRTT. The graphs showed the effects of different dosage of RX821002 
(0, 0.05 and 0.1 mg/kg) on the performance of 5-CSRTT (N = 12) in the aspects of correct response rate (A), premature 
response (B), omission rate (C), correct latency (D) and magazine latency (E). Open bars depicted saline vehicle controls, 
oblique lattice bars depicted RX821002 at 0.05 mg/kg, and black bars depicted RX821002 at 0.1 mg/kg. Values are presented as 
mean+SEM. * P < 0.05.
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premature response; F(2,22) = 0.65 for omission rate;
F(2,22) = 0.40 for correct latency and F(2,22) = 0.58 for
magazine latency].
Effects of RBX on 5-CSRTT following pretreatment with 
PRA
Effects of RBX on performance of the 5-CSRTT in the con-
dition of pretreatment of alpha-1 adrenergic receptor
antagonist PRA (0.3 mg/kg) were examined (see Figure 5).
There was a significant effect of RBX × PRA in correct
response [F(1,9) = 6.47, p < 0.05]. Simple main effect was
found in the condition of RBX without PRA [F(1,9) =
5.43, p < 0.05]. Further comparisons revealed there were
differences between RBX-saline and saline-saline [t(1,9) =
2.34, p < 0.05], and RBX-saline and RBX-PRA [t(1,9) =
2.66, p < 0.05]. For premature response, main effects were
found in RBX [F(1,9) = 10.98, p < 0.01] and PRA [F(1,9)
= 7.11, p < 0.05] without interactions. For omission rate,
main effects were found in RBX [F(1,9) = 11.42, p < 0.01]
and PRA [F(1,9) = 11.61, p < 0.01] without interactions.
For correct latency and magazine latency, main effect of
RBX was found significant [F(1,9) = 9.05, p < 0.05 and
F(1,9) = 11.78, p < 0.01].
Effects of RBX on 5-CSRTT following pretreatment with 
RX821002
Effects of RBX on performance of the 5-CSRTT in the con-
dition of pretreatment of alpha-2 adrenergic receptor
antagonist RX821002 (0.1 mg/kg) were examined (see
Figure 6). In correct response, there was little effect on
RBX, RX821002 or RBX × RX821002. In premature
response, There was a significant effect of RBX ×
RX821002 [F(1,9) = 6.08, p < 0.05]. Simple main effect
was found in the condition of RX821002 without RBX
[F(1,9) = 5.77, p < 0.05]. Further comparisons revealed
there were differences between saline-saline and saline-
RX821002 [t(1,9) = 2.72, p < 0.05), and saline-RX821002
and RBX-RX821002 (t(1,9) = 4.11, p < 0.01). For omis-
sion rate, There was a significant effect of RBX ×
RX821002 [F(1,9) = 11.62, p < 0.01]. Simple main effect
was found in the condition of RBX without RX821002
[F(1,9) = 5.85, p < 0.05]. Further comparisons revealed
there were differences between saline-saline and RBX-
saline [t(1,9) = 6.56, p < 0.001], and RBX-saline and RBX-
RX821002 [t(1,9) = 5.93, p < 0.001]. For correct latency
and magazine latency, main effect of RBX was found sig-
nificant [F(1,9) = 8.77, p < 0.05 and F(1,9) = 6.30, p <
0.05].
Discussion
The present study described NET inhibitor RBX could
improve attentional function and the ability of response
control in a task requiring visual accuracy and the man-
agement of impulsiveness. The contributions of alpha-1
and alpha-2 adrenoceptors in the RBX effect were exam-
ined. While the alpha-1 effect was mainly responsible for
attentional accuracy, Alpha-2 adrenergic receptors con-
tributed to the adjustment of impulsiveness. Interpreta-
tions of these findings were discussed as the following.
For protocol used in the present study, behavior was
mainly controlled by the rats' attentional function and
their motor impulsiveness. For example, rats made their
correct response largely depending on their sustained and
divided attentional functions. At the same time, rats also
had to restrain their impetuous nature for not nose-pok-
ing hastily, which was representative of their ability to
control motor impulsiveness. Attentional impairment has
been considered for a long time as one of the major cog-
nitive psychopathologies of major depression [19-21].
The beneficial effect of NET inhibitor reboxetine found in
this study was in line with the concept that the attentional
and executive disturbance in major depressive patients
could be alleviated following the treatment of antidepres-
sant medications [22].
In general it takes al least two weeks for antidepressants to
attain their clinical efficacy. Accordingly in the present
study, we demonstrated RBX treatment for unremittingly
two weeks appeared to produce different effects on atten-
tion and impulsiveness. As their impulsiveness remained
unaffected, rats under RBX treatment became less atten-
tive. Attentional performance and impulse control had
been assumed based on distinctive neurobiological mech-
anisms and they both depended largely on the integrity of
prefrontal cortex, particularly dorsa-lateral prefrontal cor-
tex. The present experiment demonstrated that when RBX
was combined with alpha-2 antagonist RX821002, the lat-
ter successfully reversed the RBX improved impulse con-
trol in 5-CSRTT. The result supported the idea that when
analyzing the improvement of rats' attentional perform-
ance, selection response and impulse control might be
involved in a dissociated manner [18]. The present study
continued to extend the idea and found alpha-1 and
alpha-2 adrenoceptors might contribute in a different way
to accuracy and vigor responding.
Central noradrenergic system was considered significantly
being involved in the regulation of attentional function.
For the knowledge to date, alpha-1 adrenoceptor revealed
a greater extent than alpha-2 adrenoceptor in modulating
response accuracy in the task concentrating subject's
attention [23]. Systemic administration of alpha-1 agonist
St-587 improved the response accuracy and this effect
could be blocked by alpha-1 receptor antagonist prozasin
[24]. Activation of alpha-1 adrenergic receptor manifested
importantly in conditions requiring attention. For exam-
ple, alpha-1 adrenergic activation facilitated cognitive per-
formance of rats in situation requiring a variety of arousal
levels, such as attentional set-shifting task [25]. TheJournal of Biomedical Science 2009, 16:72 http://www.jbiomedsci.com/content/16/1/72
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Effects of RBX in combination with PRA on the performance of 5-CSRTT Figure 5
Effects of RBX in combination with PRA on the performance of 5-CSRTT. The graphs showed the effects of RBX 10 
mg/kg in combination with PRA 0.3 mg/kg (N = 10) on the performance of 5-CSRTT in the aspects of correct response (A), 
premature response (B), omission rate (C), correct latency (D) and magazine latency (E). Open bars depicted saline + saline, 
oblique lattice bars depicted RBX + saline, reticular bars depicted saline + PRA, and black bars depicted RBX + PRA. Values are 
presented as mean+SEM. * P < 0.05.
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Effects of RBX in combination with RX821002 on the performance of 5-CSRTT Figure 6
Effects of RBX in combination with RX821002 on the performance of 5-CSRTT. The graphs showed the effects of 
RBX 10 mg/kg in combination with RX821002 0.1 mg/kg (N = 10) on the performance of 5-CSRTT in the aspects of correct 
response rate (A), premature response (B), omission rate (C), correct latency (D) and magazine latency (E). Open bars 
depicted saline + saline, oblique lattice bars depicted RBX + saline, reticular bars depicted saline + RX821002, and black bars 
depicted RBX + RX821002. Values are presented as mean+SEM. * P < 0.05.
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present study was in the other way to demonstrate that the
alpha-1 adrenergic receptor was crucial for both sustained
and divided attentional functions [23,24,26,27]. Appar-
ently in 5-CSRTT of the present study, the action of motor
impulsiveness occurred prior to the emergency of any cor-
responding visual signal, therefore it inherited with antic-
ipatory character. Alpha-1 antagonist PRA when given
alone had a minor effect on the anticipatory response in
5-CSRTT. Previously PRA at the dose of 0.1 mg/kg was
found unable to reverse the effect of alpha-1 agonist St-
587 in reducing premature responses [24]. This was con-
sistent with what happened in the present experiment as
PRA at the same dose could not abolish the RBX induced
reduction of premature response.
Taken together it appeared that the alpha-1 adrenoceptor
contributed little in controlling anticipatory actions in sit-
uation requiring sustained and divided attentions. On the
other hand, the role of alpha-2 adrenoceptor in the regu-
lations of motor impulse control might be more impor-
tant. Our results demonstrated that although alpha-2
adrenoceptor antagonist per se was little to do with pre-
mature responding as revealed before [4], it may poten-
tially help to adjust the effect of NET inhibitor. Possible
mechanisms might be related to either an increase of
norepinephrine availability following presynaptic auto-
regulation [28], or the postsynaptic mechanism through
which the alpha-2 adrenoceptor antagonist abolished the
subsequent effect following RBX induced norepinephrine
surge. The former seemed less plausible due to the follow-
ing considerations. First, the effects of an alpha 2-adreno-
ceptor agonist dexmedetomidine on anticipatory
responses were found no difference between controls and
rats with central NA depleted by N-(2-chloroethyl)-N-
ethyl-2-bromobenzy-lamine (DSP-4). Second, alpha-2
adrenoceptor may function as a terminal presynaptic
autoreceptor to restrain NE release [29]; or heteroreceptor
at 5HT terminal to hold back 5HT release [29,30]. In the
present study if the enhanced ability of impulse control by
RBX was attributable to the acceleration of 5HT neuronal
activity via alpha-1 adrenoceptor at 5HT cell body, the
activation of alpha-2 autoreceptor located on NA terminal
on the other hand would hold back the release of NE, that
in turn attenuated alpha-1 activation therefore rats should
be more impulsive.
In attentional task as 5-CSRTT, measures in fact provided
valuable information other than visual accuracy and
impulse control. For example, correct latency generally
refers to the reaction time elapsed from coming out visual
signal to the rats' nose-poking the correct hole. Increase of
correct latency suggests a longer motor readiness or
hypoactivity [31]. Compared to correct latency, magazine
latency refers to the reaction time elapsed from coming
out the food pallet to the collection of that reward, nor-
mally reflecting animals' motivational state. In the present
experiment, correct latency was found longer in both
treatment conditions, RBX alone and RBX combined with
PRA or RX821002. Magazine latency was also longer fol-
lowing RBX treatment. The similar impacts over correct
response time and food collecting time suggested the reac-
tion time was prolonged, no matter the target stimulus
was reward itself or its antecedent. However, the cognitive
benefit of RBX in reducing the premature response was
unlikely caused by the prolonged reaction time since the
elapse duration of correct reaction time was around 200
ms (i.e., 0.2 second), far from the time scale of impulsive-
ness indexed by the premature response counted within
the scale of 5 sec ITI.
Along with many other antidepressants, the peripheral
effect of RBX is well worth considering in which auto-
nomic side effects such as dry mouth and adjusted sympa-
thetic vasomotor tone had been reported previously
[32,33]. This might elicit the concerning that the result
obtained form the present experiment might be contrib-
uted to a degree by peripheral effects of RBX. Although
this issue was worth taking into account; it was not much
likely to confound the interpretation of the result. In an
experimental design such as 5CSRTT, it was the level of
motor function more responsible for influencing the
result of 5-CSRTT. In the present study, animals' motor
function was preserved well since both correct and maga-
zine latencies did not prolong following the administra-
tion of RBX.
In summary, the present study demonstrated NET inhibi-
tor RBX may exhibit some potential benefit in the aspects
of both response accuracy and behavioral inhibition.
Future studies would suggest validating the argument
obtained from the present study in a more comprehensive
way, for example, examining the effect of RBX on signal
transduction pathways mediated by alpha-1 and -2 adren-
ergic receptors.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YPL and YLL carried out the 5-CSRTT work. CHC was
responsible for drug administration. YCK and STC were
responsible for clinical interpretation. YPL and CST con-
ceived of the study, and participated in its design and
coordination. All authors read and approved the final
manuscript.
Acknowledgements
This study was supported by the National Science Council (NSC 94-2320-
B-016-025) and a grant of the National Defense Medical Center (DOD 95-
04-03). Special thanks should go to Pfizer Global Research and Develop-
ment for their kindly donation of RBX. Thanks should also go to Mr. J. W. Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Biomedical Science 2009, 16:72 http://www.jbiomedsci.com/content/16/1/72
Page 12 of 12
(page number not for citation purposes)
Yang at the National Defense Medical Center for the assistance in the work 
of editing and figure illustration.
References
1. Zhou J: Norepinephrine transporter inhibitors and their ther-
apeutic potential.  Drugs Future 2004, 29:1235-1244.
2. Debiec J, LeDoux JE: Noradrenergic signaling in the amygdala
contributes to the reconsolidation of fear memory: treat-
ment implications for PTSD.  Ann N Y Acad Sci 2006,
1071:521-524.
3. Mash DC, Ouyang Q, Qin Y, Pablo J: Norepinephrine transporter
immunoblotting and radioligand binding in cocaine abusers.
J Neurosci Methods 2005, 143:79-85.
4. Wilens TE: Mechanism of action of agents used in attention-
deficit/hyperactivity disorder.  J Clin Psychiatry 2006, 67(Suppl
8):32-38.
5. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann
WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A, Carfagna N,
McArthur RA: Reboxetine: a pharmacologically potent, selec-
tive, and specific norepinephrine reuptake inhibitor.  Biol Psy-
chiatry 2000, 47:818-829.
6. Connor TJ, Kelliher P, Harkin A, Kelly JP, Leonard BE: Reboxetine
attenuates forced swim test-induced behavioural and neuro-
chemical alterations in the rat.  Eur J Pharmacol 1999,
379:125-133.
7. Krell HV, Leuchter AF, Cook IA, Abrams M: Evaluation of rebox-
etine, a noradrenergic antidepressant, for the treatment of
fibromyalgia and chronic low back pain.  Psychosomatics 2005,
46:379-84.
8. Pliszka SR, McCracken JT, Maas JW: Catecholamines in atten-
tion-deficit hyperactivity disorder: current perspectives.  J
Am Acad Child Adolesc Psychiatry 1996, 35:264-72.
9. Chamberlain SR, Sahakian BJ: The neuropsychiatry of impulsiv-
ity.  Curr Opin Psychiatry 2007, 20:255-61.
10. Leonard JA: 5 choice serial reaction apparatus.  Med Res Council
Appl Psychol Res 1959:326-359.
11. Wilkinson RT: Interaction of Noise with Knowledge of Results
and Sleep Deprivation.  J Exp Psychol 1963, 66:332-337.
12. Bushnell PJ: Behavioral approaches to the assessment of atten-
tion in animals.  Psychopharmacology (Berl) 1998, 138:231-259.
13. Carli M, Robbins TW, Evenden JL, Everitt BJ: Effects of lesions to
ascending noradrenergic neurones on performance of a 5-
choice serial reaction task in rats; implications for theories of
dorsal noradrenergic bundle function based on selective
attention and arousal.  Behav Brain Res 1983, 9:361-380.
14. Carli M, Samanin R: Serotonin2 receptor agonists and seroton-
ergic anorectic drugs affect rats' performance differently in
a five-choice serial reaction time task.  Psychopharmacology (Berl)
1992, 106:228-234.
15. Cole BJ, Robbins TW: Amphetamine impairs the discrimina-
tive performance of rats with dorsal noradrenergic bundle
lesions on a 5-choice serial reaction time task: new evidence
for central dopaminergic-noradrenergic interactions.  Psy-
chopharmacology (Berl) 1987, 91:458-466.
16. Cole BJ, Robbins TW: Effects of 6-hydroxydopamine lesions of
the nucleus accumbens septi on performance of a 5-choice
serial reaction time task in rats: implications for theories of
selective attention and arousal.  Behav Brain Res 1989,
33:165-179.
17. Passetti F, Dalley JW, O'Connell MT, Everitt BJ, Robbins TW:
Increased acetylcholine release in the rat medial prefrontal
cortex during performance of a visual attentional task.  Eur J
Neurosci 2000, 12:3051-3058.
18. Passetti F, Dalley JW, Robbins TW: Double dissociation of sero-
tonergic and dopaminergic mechanisms on attentional per-
formance using a rodent five-choice reaction time task.
Psychopharmacology (Berl) 2003, 165:136-145.
19. Thomas P, Goudemand M, Rousseaux M: Divided attention in
major depression.  Psychiatry Res 1998, 81:309-22.
20. Paelecke-Habermann Y, Pohl J, Leplow B: Attention and executive
functions in remitted major depression patients.  J Affect Disord
2005, 89:125-35.
21. Pardo JV, Pardo PJ, Humes SW, I Posner M: Neurocognitive dys-
function in antidepressant-free, non-elderly patients with
unipolar depression: alerting and covert orienting of visu-
ospatial attention.  J Affect Disord 2006, 92:71-78.
22. Constant EL, Adam S, Gillain B, Seron X, Bruyer R, Seghers A: Effects
of sertraline on depressive symptoms and attentional and
executive functions in major depression.  Depress Anxiety 2005,
21:78-89.
23. Robbins TW: The 5-choice serial reaction time task: behav-
ioural pharmacology and functional neurochemistry.  Psychop-
harmacology (Berl) 2002, 163:362-380.
24. Puumala T, Riekkinen P Sr, Sirvio J: Modulation of vigilance and
behavioral activation by alpha-1 adrenoceptors in the rat.
Pharmacol Biochem Behav 1997, 56:705-712.
25. Lapiz MD, Morilak DA: Noradrenergic modulation of cognitive
function in rat medial prefrontal cortex as measured by
attentional set shifting capability.  Neuroscience 2006,
137:1039-1049.
26. Ruotsalainen S, Haapalinna A, Riekkinen PJ Sr, Sirvio J: Dexmedeto-
midine reduces response tendency, but not accuracy of rats
in attention and short-term memory tasks.  Pharmacology Bio-
chemistry and Behavior 1997, 56:31-40.
27. Sirvio J, Mazurkiewicz M, Haapalinna M, Riekkinen AP Jr, Lahtinen H,
Riekkinen PJ: The effects of selective alpha-2 adrenergic agents
on the performance of rats in a 5-choice serial reaction time
task.  Brain Research Bulletin 1994, 35:451-455.
28. Sirvio J, Jakala P, Mazurkiewicz M, Haapalinna A, Riekkinen P Jr, Riek-
kinen PJ: Dose- and parameter-dependent effects of atipame-
zole, an alpha 2-antagonist, on the performance of rats in a
five-choice serial reaction time task.  Pharmacol Biochem Behav
1993, 45:123-129.
29. Stahl SM: Essential Psychopharmacology 2nd edition. UK: Cambridge
University Press; 2000. 
30. Civantos Calzada B, Aleixandre de Artinano A: Alpha-adrenocep-
tor subtypes.  Pharmacological Research 2001, 44:195-208.
31. Maitra KK, AK : Dasgupta Incoordination of a sequential
motor task in Parkinson's disease.  Occup Ther In 2005,
12:218-233.
32. Langworth S, Bodlund O, Agren H: Efficacy and tolerability of
reboxetine compared with citalopram: a double-blind study
in patients with major depressive disorder.  J Clin Psychopharma-
col 2006, 26:121-7.
33. Tank J, Schroeder C, Diedrich A, Szczech E, Haertter S, Sharma AM,
Luft FC, Jordan J: Selective impairment in sympathetic vaso-
motor control with norepinephrine transporter inhibition.
Circulation 2003, 107:2949-54.